Omnicare, Inc. v. NCS Healthcare, Inc.

825 A.2d 264, 2002 Del. Ch. LEXIS 131, 2002 WL 31445163
Court of Chancery of Delaware·Decided October 29, 2002·No. Civ.A. 19800, 19786·Published·Cited by 2 cases

Opinion

OPINION AND ORDER

LAMB, Vice Chancellor.

I.

These actions arise out of a proposed merger (the “Merger”) between NCS Healthcare, Inc. and a wholly owned subsidiary of Genesis Health Ventures, Inc. in which each share of NCS Class A Common Stock and Class B Common Stock is to be converted into the right to receive 0.1 share of Genesis common stock. The Class A shares and the Class B shares are identical in most respects; however, (i) the holders of Class A shares are entitled to only one (1) vote per share, while the holders of Class B shares are entitled to ten (10) votes per share and (ii) the Class B shares are subject to certain transfer restrictions that result in their automatic conversion into Class A shares when a non-permitted transfer occurs. The agreement and plan of merger among the parties (the “Merger Agreement”) was approved by the NCS board of directors (the “Board”) and executed on July 28, 2002.

After the Board approved the Merger on July 28, 2002, it also authorized the execution of two separate voting agreements among Genesis and NCS and Jon H. Outcalt, Chairman of the Board, and Kevin Shaw, President of NCS and a Board member (the “Voting Agreements”). 1 Pursuant to these agreements, Outcalt and Shaw each separately agreed to vote all of his shares in favor of the Merger and, to that end, granted an irrevocable proxy to several senior officers of Genesis “to vote all of the Shares beneficially owned by [him] in favor of the [Merger].” At the time Outcalt and Shaw signed the Voting Agreements, although neither individually held more than a majority of the NCS voting power, by virtue of their beneficial ownership of substantially all the outstanding shares of Class B Common Stock, they together controlled more than 65% of the total voting power, enough to assure ratification of the Merger Agreement.

The plaintiff in Civil Action No. 19800, Omnicare, Inc., made a proposal relating to a merger with NCS that was rejected by the Board. Omnicare has since purchased shares of NCS common stock, filed this action, and initiated a cash tender offer to acquire any and all the outstanding shares of NCS common stock. 2 Civil Action No. 19786 was filed by individual stockholders of NCS, on behalf of a class *267 of similarly situated persons. Now pending before the court are motions for partial summary judgment as to the first counts of both operative complaints seeking a declaration that the execution of the Voting Agreements and/or delivery of the irrevocable proxies found therein resulted in the automatic conversion of all shares of Class B Common Stock held by Outcalt and Shaw into shares of Class A Common Stock. If these motions are successful, the ultimate approval of the Merger will be in substantial doubt inasmuch as the Board has recently withdrawn its recommendation in favor of the Merger.

II.

Defendant NCS Healthcare, Inc. was incorporated in Delaware in 1995 as a wholly owned subsidiary of a privately held Ohio corporation, Aberdeen Group, Inc. Defendants Outcalt and Shaw controlled Aberdeen through their ownership of a substantial majority of its high-vote Class B Common Stock. In February 1996, NCS merged with Aberdeen, with NCS as the surviving corporation. In that merger, the NCS certificate of incorporation was amended and restated, and that Restated and Amended Certificate of Incorporation is the current charter of NCS (the “Charter” or “NCS Charter”). Shortly thereafter, NCS engaged in an initial public offering.

There are three provisions in the NCS Charter of relevance to this litigation, all of which are found within Article IV, Section 7 thereof. 3 Section 7(a) is a transfer provision that provides:

[N]o person holding any shares of Class B Common Stock may transfer, and the Corporation shall not register the transfer of, such shares of Class B Common Stock or any interest therein, whether by sale, assignment, gift, bequest, appointment or otherwise, except to a “Permitted Transferee” 4 of such person.

Section 7(d) of the Charter provides for the automatic conversion into Class A shares of any Class B shares transferred to anyone other than a Permitted Transferee. Specifically, Section 7(d) states:

Any purported transfer of shares of Class B Common Stock other than to a Permitted Transferee shall automatically, without any further act or deed on the part of the Corporation or any other person, result in the conversion of such *268 shares into shares of Class A Common Stock on a share-for-share basis, effective on the date of such purported transfer.

Finally, Section 7(c)(5) provides that the giving of a proxy in connection with a solicitation of proxies does not constitute a transfer of Class B stock. In particular, Section 7(c)(5) states:

The giving of a proxy in connection with a solicitation of proxies subject to the provisions of Section 14 of the Securities Exchange Act of 1934 (or any successor provision thereof) and the rules and regulations promulgated thereunder shall not be deemed to constitute the transfer of an interest in the shares of Class B Common Stock which are the. subject of the proxy.

In their motion for partial summary judgment, Omnicare and the stockholder-plaintiffs all argue that Outcalt’s and Shaw’s Class B shares were automatically converted in Class A shares when the Voting Agreements were signed. In making this argument, they rely principally on Sections 2(b) and 2(c) of those agreements, which read, in relevant part, as follows:

(b) AGREEMENT TO VOTE.... [T]he Stockholder hereby irrevocably and unconditionally agrees to vote or to cause to be voted all of the Shares then owned of record or beneficially by him at the Company Stockholders Meeting and at any other annual or special meeting of shareholders of the Company where any such proposal is submitted, and in connection with any written consent of stockholders, (A) in favor of the [Merger] and (B) against (i) approval of any proposal made in opposition to or in competition with the [Merger] and the transactions contemplated by the Merger Agreement, (ii) any merger, consolidation, sale of assets, business combination, share exchange, reorganization or recapitalization of the Company or any of its subsidiaries, with or involving any party other than as contemplated by the Merger Agreement, (iii) any liquidation or winding up of the Company, (iv) any extraordinary dividend by the company, (v) any change in the capital structure of the Company (other than pursuant to the Merger Agreement) and (vi) any other action that may reasonably be expected to impede, interfere with, delay, postpone or attempt to discourage the consummation of the transactions contemplated by the Merger Agreement. ...
(c) GRANTING OF PROXY....

Free access — add to your briefcase to read the full text and ask questions with AI

Omnicare, Inc. v. NCS Healthcare, Inc., 825 A.2d 264, 2002 Del. Ch. LEXIS 131, 2002 WL 31445163 (Del. Ct. App. 2002).

825 A.2d 264 (Omnicare, Inc. v. NCS Healthcare, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

In re MFW Shareholders Litigation
67 A.3d 496 (Court of Chancery of Delaware, 2013)
In Re NCS Healthcare, Inc., Shareholders Litigation
825 A.2d 240 (Court of Chancery of Delaware, 2002)